Emulations of oncology trials using real-world data: a systematic literature review
American Journal of Epidemiology · 2025
DOI: 10.1093/aje/kwae346 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift American Journal of Epidemiology, 2025. Verfasst von Jennifer R Rider und 20 weiteren Autor:innen. Beteiligte Einrichtung: Aetion, Inc., New York, NY 10001, United States. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Medical Oncology, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
By evaluating published emulations of oncology randomized control trial (RCT) studies in which both the active and comparator groups are sourced from real-world data (RWD) and target trial results are available for benchmarking, this systematic review aims to gain insight into factors related to emulation performance. Thirteen oncology emulation studies using various types of RWD were identified through an online database search of PubMed through 2022. Based on the ROBINS-I tool, most studies (n = 8) had a serious risk of overall bias driven by risk of bias from confounding. Approximately half of the studies (n = 6) fully proxied the RCT entry criteria. Of 11 RWD studies that provided sufficient detail to quantify emulation performance, the emulation hazard ratio (HR) estimate fell within the 95% confidence interval (CI) of the trial estimate in 9 of the studies. There were no clear trends between risk of bias or degree to which the entry criteria were proxied and emulation performance. Findings may have been influenced by publication bias and researcher degrees of freedom, as only one emulation study preregistered its protocol. Tools for comprehensively characterizing factors that affect emulation performance, including the real-world clinical context as it relates to the RCT research question, are needed to evaluate the feasibility of a RCT emulation. This article is part of a Special Collection on Pharmacoepidemiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Aetion, Inc., New York, NY 10001, United States.
- ConcertAI, 1120 Massachusetts Avenue, Cambridge, MA 02138, United States.
- xCures, Inc., Oakland, CA 94612, United States.
- Center for Observational Research, Amgen, San Francisco, CA 94080, United States.
- Janssen Research & Development, LLC, Brisbane, CA 94005, United States.
- Bayer Pharmaceuticals, Whippany, NJ 07981, United States.
ORCID-Profile: Jennifer R Rider
Zitieren
APA
Rider, J. R., Wasserman, A., Slipski, L., Carrigan, G., Harvey, R., Jiao, X., McRoy, L., Pace, N. D., Becnel, L., Bruno, A., Eckert, J. C., Hodgkins, P., Jain, P., Merola, D., Ovbiosa, O. E., Natanzon, Y., Pinheiro, S., Quinn, J., Rodriguez-Watson, C., …, & Coalition to Advance RWE in RCT Emulations (CARE) Initiative (2025). Emulations of oncology trials using real-world data: a systematic literature review. American Journal of Epidemiology. https://doi.org/10.1093/aje/kwae346
Vancouver
Rider JR, Wasserman A, Slipski L, Carrigan G, Harvey R, Jiao X, et al. Emulations of oncology trials using real-world data: a systematic literature review. American Journal of Epidemiology. 2025. doi:10.1093/aje/kwae346
BibTeX
@article{Rider2025,
author = {Rider, Jennifer R and Wasserman, Asher and Slipski, Lukas and Carrigan, Gillis and Harvey, Raymond and Jiao, Xiaolong and McRoy, Lynn and Pace, Nelson D and Becnel, Lauren and Bruno, Amanda and Eckert, Joy C and Hodgkins, Priscilla and Jain, Purva and Merola, David and Ovbiosa, Osayi E and Natanzon, Yanina and Pinheiro, Simone and Quinn, Jameson and Rodriguez-Watson, Carla and Campbell, Ulka and Coalition to Advance RWE in RCT Emulations (CARE) Initiative, Coalition to Advance RWE in RCT Emulations (CARE) Initiative},
title = {Emulations of oncology trials using real-world data: a systematic literature review},
journal = {American Journal of Epidemiology},
year = {2025},
doi = {10.1093/aje/kwae346}
}
EUVIMED